ADPKD
This Freely Filtered episode discusses the KDIGO guideline draft for autosomal dominant polycystic kidney disease (ADPKD).
Novartis will acquire Regulus Therapeutics, developer of ADPKD therapeutic candidate farabursen, a novel oligonucleotide.
Lupin's generic tolvaptan tablets are now FDA-approved for treating autosomal dominant polycystic kidney disease (ADPKD).
KDIGO has published its first guideline on the evaluation, management, and treatment of ADPKD.
A study examined the effects of adding dapagliflozin to treatment with tolvaptan in patients with ADPKD.
A study examined whether serum phosphate levels could predict kidney outcomes in patients with ADPKD.
An exploratory pilot study aimed to identify and evaluate potential proinflammatory biomarkers in patients with ADPKD.
A post hoc analysis of TEMPO 3:4 results examined longer-term effects of tolvaptan on TKV and eGFR in patients with ADPKD.
Data regarding mortality specific to patients with autosomal dominant polycystic kidney disease (ADPKD) are limited.
A team evaluated the Mayo imaging classification system's ability to predict kidney outcomes in an ADPKD cohort.
Researchers compared factors associated with intracranial aneurysm in patients with ADPKD.
The FDA granted orphan drug designation to AP303 for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
Advertisement
Knowledge Hubs
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.